2.075
5.88%
-0.135
Mersana Therapeutics Inc stock is traded at $2.075, with a volume of 1.51M.
It is down -5.88% in the last 24 hours and down -0.95% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
See More
Previous Close:
$2.21
Open:
$2.22
24h Volume:
1.51M
Relative Volume:
1.50
Market Cap:
$263.75M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-1.0172
EPS:
-2.04
Net Cash Flow:
$-171.05M
1W Performance:
-17.79%
1M Performance:
-0.95%
6M Performance:
-23.81%
1Y Performance:
+34.19%
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
MRSN | 2.075 | 263.75M | 36.86M | -171.67M | -171.05M | -2.04 |
VRTX | 467.21 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 761.02 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 564.61 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 230.30 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.69 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
Jul-27-23 | Downgrade | Truist | Buy → Hold |
Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
Jun-15-23 | Initiated | Guggenheim | Buy |
Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-20-23 | Initiated | Citigroup | Buy |
Nov-21-22 | Initiated | Truist | Buy |
Oct-15-21 | Resumed | BTIG Research | Buy |
Aug-30-21 | Initiated | H.C. Wainwright | Buy |
Mar-31-21 | Initiated | Credit Suisse | Neutral |
Dec-03-20 | Initiated | Stifel | Buy |
Sep-29-20 | Resumed | JP Morgan | Neutral |
Apr-29-20 | Initiated | BTIG Research | Buy |
Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
May-08-18 | Initiated | Robert W. Baird | Outperform |
Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Mersana Therapeutics transferred with Buy rating at Citi - MSN
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated by Analysts at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.63 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey
Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
FANG Index (FGU25) Quote - The Globe and Mail
Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates - MarketWatch
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Mersana Therapeutics (MRSN) Q3 2024 Earnings: EPS Loss of $0.09 Beats Estimates, Revenue Surges to $12.6M - GuruFocus.com
Mersana Therapeutics Reports Progress in Cancer Treatments - TipRanks
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewswire
Mersana Therapeutics, Inc. Provides Business Update - Marketscreener.com
Earnings Preview For Mersana Therapeutics - Benzinga
Mersana Therapeutics presents new data on XMT-2056 - BioWorld Online
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Price Target from Brokerages - Defense World
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly? - Simply Wall St
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00 - MarketBeat
Mersana Therapeutics (MRSN) to Release Earnings on Wednesday - MarketBeat
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 - GlobeNewswire
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 - GlobeNewswire Inc.
MRSN (Mersana Therapeutics) Revenue : $29.94 Mil (TTM As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 - Investing.com India
Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 By Investing.com - Investing.com South Africa
SG Americas Securities LLC Reduces Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc’s Market Journey: Closing Weak at 2.05, Down -2.38 - The Dwinnex
Exchange Traded Concepts LLC Acquires 41,586 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mersana Therapeutics Inc Stock (MRSN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Bala Mohan | SVP, Chief Development Officer |
Oct 28 '24 |
Sale |
1.90 |
1,884 |
3,580 |
54,731 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):